Since the recognition of human acquired immune deficiency syndrome, numerous classes of
pharmacologic therapeutics have been developed to manage the disease. Current therapy …

The chemokine coreceptor 5 (CCR5) antagonists are antiretroviral agents with an
extracellular, host-targeted mechanism of action against HIV. Maraviroc, the first-in-class …

The human chemokine receptors, CCR5 and CXCR4, are potential host targets for
exogenous, small-molecule antagonists for the inhibition of HIV-1 infection. HIV-1 strains …

Introduction: The chemokine receptor CCR5 has garnered significant attention in recent
years as a target to treat HIV infection largely due to the approval and success of the drug …

In the context of emerging resistance to antiretroviral agents in HIV medicine, the
development of new drugs classes with a novel mechanism of action remains essential. The …

The human immunodeficiency virus (HIV) causes acquired immumodeficiency syndrome
(AIDS), one of the worst global pandemic. The virus infects human CD4 T cells and …

Introduction: The discovery of CC-chemokine receptor 5 (CCR5) as a human
immunodeficiency virus type 1 (HIV-1) coreceptor opened a new avenue to exploit CCR5 as …

Pfizer Inc is developing maraviroc, a CCR5 receptor antagonist for the treatment of HIV-1
infection and rheumatoid arthritis. In April 2007, the FDA advisory committee voted to …

Treatment of HIV-1 infection has produced dramatic success for many patients.
Nevertheless, viral resistance continues to limit the efficacy of currently available agents in …

Importance of the field: The HIV/AIDS epidemic and the resultant therapeutic efforts have
continued to evolve over the last several years. The continued challenges in vaccine …